VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
22.28(c) 23.09(c) 22.71(c) 24.93(c) 24.36 Last
770 105 658 273 919 849 1 089 901 740 901 Volume
-1.55% +3.64% -1.65% +9.78% -2.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 548 M - -
Net income 2022 314 M - -
Net cash position 2022 2 110 M - -
P/E ratio 2022 10,8x
Yield 2022 -
Sales 2023 307 M - -
Net income 2023 -338 M - -
Net cash position 2023 1 797 M - -
P/E ratio 2023 -10,2x
Yield 2023 -
Capitalization 3 300 M 3 300 M -
EV / Sales 2022 0,77x
EV / Sales 2023 4,89x
Nbr of Employees 444
Free-Float 86,6%
More Financials
Company
Vir Biotechnology, Inc. is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. It has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The Company's pipeline consists of... 
More about the company
Ratings of Vir Biotechnology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about VIR BIOTECHNOLOGY, INC.
04:11pVIR BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Termination of a Mat..
AQ
05/18Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
GL
05/18Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
AQ
05/12HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy R..
MT
05/11Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
RE
05/05Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81..
MT
05/05VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/05Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81..
MT
05/05Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re..
GL
05/05Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re..
AQ
05/05Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/02INSIDER SELL : Vir Biotechnology
MT
04/27TRANSCRIPT : Vir Biotechnology, Inc. - Special Call
CI
04/27Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepa..
GL
04/27Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepa..
GL
More news
News in other languages on VIR BIOTECHNOLOGY, INC.
05/11Le rachat de Biohaven par Pfizer, pour 11,6 milliards de dollars, pourrait susciter d'a..
05/05Earnings Flash (VIR) VIR BIOTECHNOLOGY annonce un chiffre d'affaires de 1,23 milliard d..
05/05Earnings Flash (VIR) VIR BIOTECHNOLOGY annonce un chiffre d'affaires de 1,23 milliard d..
05/05Vir Biotechnology, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars..
05/02VENTE D'INITIÉS : Vir Biotechnology
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | VIR | US92764N1028 | MarketScreener
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 24,93 $
Average target price 53,29 $
Spread / Average Target 114%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Chief Accounting Officer
Vicki L. Sato Non-Executive Chairman
Phil Pang Chief Medical Officer
Herbert W. Virgin Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.-40.46%3 300
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418